Carcinoma, Pancreatic Clinical Trial
Official title:
Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis: Correlation Analysis of Prognosis and microRNA Expression
This study aims to explore the efficacy and safety of radiofrequency ablation combined with S-1 in pancreatic cancer patients with liver metastasis, as well as the correlation of serum microRNA and patients' prognosis. This protocol will be overseen by the Fudan University Institutional Review Board which has Federal Wide Assurance through the U.S. Department of Health & Human Services (Approved: April 25, 2002).
Primary Outcome Measures:
To evaluate the overall survival (OS) in pancreatic cancer patients with liver metastasis
treated with radiofrequency ablation combined with S-1.
Secondary Outcome Measures:
1. To explore the correlation of OS and serum microRNA of the patients.
2. To evaluate the progression free survival (PFS) and its correlation with serum
microRNA.
3. To observe the objective response rate (ORR) and adverse effects of the treatment.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
| Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
| Completed |
NCT04977596 -
Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer
|
||
| Recruiting |
NCT02635971 -
Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT03397342 -
MRI Only Radiation Therapy With CPAP
|
N/A |